drugset / Trial / NCT05090111

A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia

NCT05090111

Phase 1 Completed 98 enrolled Aligos Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized Study of ALG-055009 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses in Healthy Volunteers and Subjects with Hyperlipidemia

Timeline

Start
2021-12-01
Primary completion
2023-06-16
Completion
2023-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject ALG-055009 Unknown Oral